This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Topics to be covered include the growing importance of international investigators and how to more closely examine patient pool availability.
Norwood, MA (PRWEB) February 01, 2013
On February 6 at 7:45am, BioPharm Clinical™ will present an educational session on improving study feasibility and investigator selection by using patient pool demographic data at CHI’s Summit for Clinical Operations (SCOPE) in Miami, FL. BioPharm Clinical is also co-sponsoring the summit. Topics to be covered in the presentation include the growing importance of international investigators and how to more closely examine U.S. investigators as they become increasingly active in multiple studies that strain their available patients and resources.
Data analytics in BioPharm Clinical and surveys conducted by the company show…
“These trends demonstrate how critical it is for clinical operations teams to receive the tools and support they need in order to reliably assess study feasibility and to select investigators who will meet enrollment goals,” said session presenter Sean Melville, Business Development Director of BioPharm Clinical. “At SCOPE, we will show how leading global pharmaceutical companies and clinical research organizations (CROs) are leveraging new streams of data including patient pool demographics – such as those available in our +Precision™ database - to make more informed and efficient trial planning decisions.”
In addition to the presentation and co-sponsoring the summit, BioPharm Clinical will partner with Praxis to welcome attendees to a pre-conference reception at Chophouse Miami on February 4 from 6:00-9:00pm. RSVP for the annual networking event and receive a chance to win an iPad Mini.
To view the summit’s full agenda and register to attend, visit http://www.scopesummit.com.
About BioPharm Clinical
BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at http://www.biopharmclinical.com.
About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10385646.htm